Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab efficacy and safety in plaque psoriasis after biologic conversion
NCT06779097Phase 4Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of vunakizumab in plaque psoriasis, sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
vunakizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06779097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06779097.